UQ biotech start-up will target a novel immunological pathway
A new start-up aimed at discovering and developing anti-inflammatory disease medicines has been formed by The University of Queensland’s commercialisation arm UniQuest and global biotech company Molecule to Medicine (MTM).
Curlew Bio will leverage expertise from the Queensland Emory and Drug Discovery Initiative (QEDDI) and research developed by Honorary Professor Katharina Ronacher from Mater Research Institute-UQ based at the Translational Research Institute.
Professor Ronacher said her Infection, Immunity and Metabolism Research Group recently discovered a novel immunological pathway that can be drug targeted to reduce inflammation.
“This partnership is an exceptional opportunity to translate our laboratory-based research into new therapeutic possibilities that will be impactful in real-world healthcare settings,” Professor Ronacher said.
The fund has invested $1 million in Curlew Bio to develop novel small molecules for inflammatory diseases.
Curlew Bio is the second company to be formed following MTM’s expansion into Australia, with the launch of biotech start-up Lucia Bio in late 2024.
UniQuest CEO Dr Dean Moss said: “Curlew Bio builds on our relationship with MTM and our joint focus of combining world-leading science with the right people and funding to establish new biotech companies to meet unmet health challenges.”
The partnership builds on UniQuest’s ongoing relationship with MTM co-founder Dr Tom McCarthy, who was CEO and president of UQ start-up Spinifex Pharmaceuticals when it was acquired by Novartis for US$200 million in 2015.
MTM CEO Kirsty McCarthy added: “MTM has forged strong links with the exceptional drug discovery team at QEDDI and it’s an honour to be working with Professor Ronacher, a pioneer in the inflammatory field. We’ll be using MTM’s deep experience in company formation and drug development to support and accelerate the delivery of a novel anti-inflammatory modality.”
Diana Spencer, Senior Digital Content Editor, DDW
